Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Hi VC,
Dr Smith specifically stated earlier this week that our affimer binders don't sit in/attach to the region of the virus where ALL the mutations have thus far occurred.
He also stated, that in the unlikely event the current affimer doesn't pick up a specific variant, a new affimer can be produced and be ready to go within the current LFT infrastructure within 4 weeks.
Appreciate your concerns though....
Tsales - they haven't even commenced clinical validation you absolute tit.
The bigger question for me is where does this leave Mologic's own test?! Appears they have now given capacity to both Avacta and Aptamer Group.
I suggested yesterday that their test has been rejected by UK gov due to not being sensitive enough, seems highly plausible now.
Sorry, but I reluctantly disagree. Even for someone with a pretty basic knowledge of TA like myself, c235 does look like a support line.
I think the merits of charting are limited, hence I don't delve too deeply, but silly to dismiss them completely, especially when looking at support and resistance lines.
Apologies for the non AVCT related chat but does anyone have any experience with Primary Bid who uses HL as their broker?
Looking at subscribing to the CBX IPO - am I correct in thinking it needs a fund and share account in HL as can't fund straight to SIPP and/or ISA???
Ta
Sujood, why do you insist on talking rubbish? It's of course an excellent milestone for the therapeutics, but anything other than approval would of been hugely, hugely surprising - so give it a rest.
The platform and drug itself will be derisked once they can demonstrate safe and effective dosing in humans later this year, until then this is just another dot on the road to where we want to be.
Totally agree Wiggly...whilst a great milestone we know this was due in reality.
The continued delay of the TU has to be because there is info that Al either can’t yet divulge (due to NDA) or because he’s waiting on more info (data / contract etc).
Very exciting times! Newsflow in Q4 might of been a flop but you can’t argue with Q1 thus far!